Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC

Sanborn, R., Boulmay, B., Li, R., Spieler, B., Happel, K., Paustian, C., … Hilton, T. (2015). Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC. Journal for ImmunoTherapy of Cancer, 3(Suppl 2), P435. https://doi.org/10.1186/2051-1426-3-s2-p435